12.4 Obesity and Metabolic Disease

Obesity and metabolic dysfunction–associated steatotic liver disease sit on every FNP panel. The TCO will not give you a separate obesity-chapter score, but Implementation (pharmacotherapy, referral, education) and Evaluation (weight, A1c, ALT, FIB-4) will. Treat obesity as a chronic disease, not a character flaw, and treat metabolic syndrome as a cluster of problems you actually manage, not a billing phrase that excuses ignoring the statin.

Measure more than a single BMI

BMI remains the screening number: overweight 25.0–29.9, obesity class I 30.0–34.9, class II 35.0–39.9, class III ≥40 kg/m². Use ethnicity-aware judgment: many Asian adults accrue metabolic risk at lower BMI (diabetes screening often starts at BMI ≥23 in those groups). BMI under-calls risk in a central-obesity, normal-BMI adult and over-calls it in a muscular athlete.

Add waist circumference. In the United States, >35 inches (88 cm) in women and >40 inches (102 cm) in men mark abdominal obesity and raise cardiometabolic risk at any BMI. Measure standing, at the iliac crest, after a normal expiration — not a guess from the last pair of jeans.

Obesity is a disease with genetics, environment, medications (insulin, sulfonylureas, many antipsychotics, glucocorticoids, some anticonvulsants), sleep loss, and social determinants. Document it as a problem. Offer treatment the same way you offer treatment for hypertension. Shame is not a pharmacologic class.

Intensive lifestyle is still the base layer

A 5–10% weight loss improves glycemia, blood pressure, triglycerides, and steatosis. Intensive lifestyle means a calorie deficit the patient can execute, 150 minutes or more of moderate activity plus resistance work, sleep, alcohol review, and a hard look at obesogenic prescriptions. Refer to a dietitian or an intensive behavioral program when one exists. Do not prescribe eat less, move more as the entire Implementation and then blame the patient at the 3-month visit.

Lifestyle is necessary and often not sufficient. Saying try harder for six more months in a person with BMI 42, diabetes, and failed structured attempts is delay, not conservatism. Pair lifestyle with medication or a surgical referral when indications are already met.

Pharmacotherapy: who qualifies and what is high-yield in 2026

Anti-obesity pharmacotherapy is indicated at BMI ≥30, or BMI ≥27 with a weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, OSA, MASLD, osteoarthritis that limits activity). Current high-yield agents are GLP-1 receptor agonists (semaglutide 2.4 mg weekly for obesity) and dual GIP/GLP-1 agonists (tirzepatide), which produce the largest mean weight loss among approved primary-care options and also treat type 2 diabetes when that is on the list. Older options still exist: orlistat (GI fat malabsorption; fat-soluble vitamin counseling), phentermine (short-term sympathomimetic; avoid in uncontrolled hypertension and CAD), phentermine/topiramate, and naltrexone/bupropion (avoid in uncontrolled hypertension and in patients on opioids).

Counsel the same GI titration, gallbladder, and thyroid C-cell / MEN2 boxed-warning story you already know from section 12.2. These drugs are chronic therapy; weight usually returns when they stop. Do not present them as a 12-week jump start. Review contraception — rapidly changing weight and some combinations affect pregnancy planning, and some agents are teratogenic. Stop or switch if there is no meaningful response after an adequate trial at a tolerated dose — do not escalate forever on a nonresponder.

Cost, supply, and compounding-pharmacy substitutes are real clinic problems. The exam still wants the indication, the comorbidity threshold, and the safety counseling, not a copay.

Bariatric surgery referral — typical U.S. criteria

State these as typical U.S. referral thresholds, not as a law of nature: refer for evaluation when BMI ≥40, or BMI ≥35 with a serious comorbidity (type 2 diabetes, OSA, poorly controlled hypertension, MASLD with fibrosis concern). Some metabolic-surgery pathways now consider lower BMI in selected type 2 diabetes; if the stem is a classic primary-care item, the 40 / 35-plus-comorbidity pair is the expected answer. Referral is for evaluation, not an FNP-performed bypass. Preoperative work includes glycemic optimization, smoking cessation, nutrition, and a mental-health screen. Postoperative primary care watches dumping, micronutrients (B12, iron, vitamin D, calcium, thiamine), pregnancy timing, and the sudden drop in insulin or sulfonylurea requirement — hypoglycemia is an early postoperative trap.

MASLD (formerly NAFLD): suspect, score, refer

Metabolic dysfunction–associated steatotic liver disease (MASLD), formerly NAFLD, is hepatic steatosis with cardiometabolic risk and little or no alcohol. Suspect it when type 2 diabetes, obesity, mixed hyperlipidemia, or a persistent mild-to-moderate ALT elevation appears, or when ultrasound already said fatty liver. History must quantify alcohol so you do not miss alcohol-associated liver disease.

FIB-4 is the primary-care fibrosis screen: it uses age, AST, ALT, and platelet count. A low FIB-4 makes advanced fibrosis unlikely — stay in primary care, treat weight, glucose, lipids, and alcohol, and repeat periodically. An indeterminate or high FIB-4 needs elastography or hepatology referral, not another 3 years of watch the ALT. Refer also for ALT that keeps rising, jaundice, low albumin, high INR, thrombocytopenia, or uncertainty about the diagnosis.

Treatment of MASLD in primary care is weight loss (7–10%), glycemic and lipid control, alcohol minimization, and — when diabetes is present — agents with liver or weight benefit (GLP-1 RA / dual agonists; pioglitazone in selected patients without heart failure). Specialty drugs for MASH with fibrosis exist and belong with hepatology. Do not prescribe herbal liver cleanses.

Metabolic syndrome is a cluster, not a plan

Metabolic syndrome is commonly three of five: elevated waist, elevated triglycerides, low HDL, elevated blood pressure, and elevated fasting glucose (or treated hypertension or treated hyperglycemia, depending on the definition you were taught). Naming the syndrome does not replace treating the pieces.

Do not skip an indicated high-intensity statin in a 58-year-old with diabetes and an LDL-C of 142 because we are focusing on weight this year. Do not ignore a blood pressure of 154/92 because the GLP-1 RA might fix it later.

Vignette. A 52-year-old with BMI 36, waist 44 inches, triglycerides 240 mg/dL, HDL 36 mg/dL, BP 148/90, fasting glucose 118 mg/dL, and an ALT of 62 has obesity, prediabetes, and probable MASLD. Calculate FIB-4. Offer intensive lifestyle and discuss obesity pharmacotherapy (BMI ≥30). Treat blood pressure now. Discuss a statin using a formal risk calculation, not a vibe. Repeat glucose testing because 118 mg/dL is prediabetes, not a free pass. That is the plan. Metabolic syndrome — return in 1 year is not.

A second common stem is the 47-year-old with BMI 27.4, treated hypertension, and OSA who asks about an injection for weight. That person meets the ≥27-plus-comorbidity pharmacotherapy threshold even though BMI is not 30. A third is the 44-year-old with BMI 41 and no other diagnosis: bariatric referral is already on the table alongside lifestyle and medication, not after another undocumented decade of trying.

Evaluation is weight trend, waist, A1c or fasting glucose, blood pressure, lipids, FIB-4 or ALT trajectory, and medication adverse effects. If the needle does not move, change the intensity of the intervention — do not write a longer lecture.